Nirsevimab 100 mg syringe shortage has resulted in updated guidance from the Centers for Disease Control and Prevention (CDC) for how to prioritize nirsevimab administration. Per their guidance, 100 mg doses should be reserved for infants less than 6 months old and infants with underlying conditions that place them at highest risk for severe RSV disease.